The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Mon, 29th Mar 2021 09:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Destiny Pharma PLC, up 27% at 203.20 pence, 12-month range 29.1p-250p. 12-month high was hit earlier on Monday. The biotechnology firm reports data which found its nasal gel may be effective in preventing post-surgical bacterial infections. Results from a Phase 2b trial of XF-73 meet the primary efficacy endpoint. It shows a 99.5% decline in staphylococcus aureus bacterial nasal carriage, a "very effective reduction by accepted clinical measures", Destiny says. Compared to a placebo, it shows a greater than 99% reduction.

----------

Europa Metals Ltd, up 13% at 12.98p, 12-month range 4.25p-30.00p. The Australian mining projects developer reports a widened interim pretax loss but says there does not currently appear to be any material impact on the company or any significant uncertainties as a result of the coronavirus pandemic. Posts pretax loss of AUD1.7 million - about USD1.3 million - for the six months to the end of 2020, compared to AUD1.4 million loss a year earlier.

----------

Blackbird PLC, up 10% at 26.95p, 12-month range 9.5p-29.65p. The developer and seller of cloud video editing platforms says BT has chosen it for "ultra-fast and sustainable" cloud native video editing and publishing. Blackbird will work in conjunction with Pete Harvey, BT's head of digital media content operations. Harvey will use Blackbird to access and edit multiple live broadcast streams of sports and other content for the "fast" production of assets for downstream distribution to over the top and video on demand channels.

----------

AIM - LOSERS

----------

RA International Group PLC, down 16% at 41.24p, 12-month range 27.2p-72.5p. The remote site services provider notes a further escalation in hostile activity in the Cabo Delgado province, northern Mozambique, near to where the company's operations are based. Says security concerns, compounded by the pandemic and extreme weather, have led to delays to the overall energy related project in the region and to the suspension of its contract to build and operate an 1,800-person camp, where an extension of the initial two-year tenancy contract is under negotiation. "Given the escalation in hostilities in the area in recent days, the directors of the company now expect there will be further delays in the project that are likely to impact on the overall financial performance of the company in the current financial year. This impact is expected, at the current time, to be up to USD10 million of revenue, which the directors expect will now be recognised in a later financial period," says Chief Executive Soraya Narfeldt.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
26 May 2023 10:51

Polarean shares down despite narrowed annual loss and optimism

(Alliance News) - Polarean Imaging PLC shares were down on Friday despite slimming its annual loss, as the company said it now will focus on gaining commercial traction and exploring further financing for its newly US Food & Drug Administration-approved Xenoview device.

Read more
25 May 2023 10:42

IN BRIEF: Destiny Pharma picks interim CEO as Clark makes quick exit

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately "to pursue new challenges". Clark will "support [Destiny] for a limited period to ensure an orderly handover." Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held "key roles" at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC.

Read more
18 May 2023 15:03

UK shareholder meetings calendar - next 7 days

Friday 19 May 
Bank of Georgia Group PLCAGM
Permanent TSB Group Holdings PLCAGM
Sancus Lending Group LtdAGM
Monday 22 May 
Blackrock Latin American Investment Trust PLCAGM
Crossword Cybersecurity PLCAGM
Judges Scientific PLCAGM
Stelrad Group PLCAGM
Venture Life Group PLCAGM
Tuesday 23 May 
888 Holdings PLCAGM
Access Intelligence PLCAGM
Arix Bioscience PLCAGM
Bank of Ireland Group PLCAGM
Big Technologies PLCAGM
Bigblu Broadband PLCAGM
Centamin PLCAGM
CT Private Equity Trust PLCAGM
Empresaria Group PLCAGM
Epwin Group PLCAGM
Forterra PLCAGM
Fresnillo PLCAGM
Fulcrum Utility Services LtdGM re issue of conversion shares
Gresham Technologies PLCAGM
Harworth Group PLCAGM
Hilton Food Group PLCAGM
hVIVO PLCAGM
HydrogenOne Capital Growth PLCAGM
IQ-AI LtdAGM
JTC PLCAGM
K3 Business Technology Group PLCAGM
Pebble Group PLCAGM
Portmeirion Group PLCAGM
PPHE Hotel Group LtdAGM
Restaurant Group PLCAGM
Shell PLCAGM
Sherborne Investors (Guernsey) C LtdAGM
TMT Investments PLCAGM
Triple Point Income VCT PLCAGM
Triple Point Social Housing REIT PLCAGM
Trustpilot Group PLCAGM
Twentyfour Income Fund LtdAGM
Wickes Group PLCAGM
Xeros Technology Group PLCAGM
Wednesday 24 May 
4imprint Group PLCAGM
Adriatic Metals PLCAGM
Arbuthnot Banking Group PLCAGM
Artisanal Spirits Co PLCAGM
Bango PLCAGM
Coca-Cola Europacific Partners PLCAGM
Deliveroo PLCAGM
Deltic Energy PLCAGM
Distribution Finance Capital Holdings PLCAGM
Dunedin Enterprise Investment Trust PLCAGM
ECSC Group PLCCourt and General Meetings re Daisy Corporate Services Trading Ltd takeover
Empiric Student Property PLCAGM
Fidelity Japan Trust PLCAGM
HICL Infrastructure PLCAGM
Horizonte Minerals PLCAGM
Intertek Group PLCAGM
Ithaca Energy PLCAGM
Kelso Group Holdings PLCAGM
Lookers PLCAGM
M&G PLCAGM
Mercantile Investment Trust PLCAGM
Microlise Group PLCAGM
Mortgage Advice Bureau Holdings PLCAGM
National World PLCAGM
Ondine Biomedical IncAGM
Petershill Partners PLCAGM
Playtech PLCAGM
Quarto Group IncAGM
Real Estate Investors PLCAGM
Tullow Oil PLCAGM
US Solar Fund PLCAGM
Zotefoams PLCAGM
Thursday 25 May 
Alliance Pharma PLCAGM
Biome Technologies PLCAGM
Capital & Regional PLCAGM
Destiny Pharma PLCAGM
Ferrexpo PLCAGM
Fevertree Drinks PLCAGM
Headlam Group PLCAGM
Henry Boot PLCAGM
Hill & Smith PLCAGM
LBG Media PLCAGM
Life Science REIT PLCAGM
LSL Property Services PLCAGM
NAHL Group PLCAGM
Petrofac LtdAGM
Pharos Energy PLCAGM
Prudential PLCAGM
Regional REIT LtdAGM
Resolute Mining LtdAGM
RM PLCAGM
S&U PLCAGM
Sabre Insurance Group PLCAGM
Schroder Asian Total Return Investment Co PLCAGM
TBC Bank Group PLCAGM
Vanquis Banking Group PLCAGM
Zinc Media Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
2 May 2023 19:22

TRADING UPDATES: Macfarlane buys A&G Holdings for GBP3.6 million

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Apr 2023 14:16

Destiny Pharma loss widens as it extends cash runway

(Sharecast News) - Biotechnology company Destiny Pharma reported a loss before tax of £7.7m in its 2022 results on Thursday, widening from £6.3m in the prior year.

Read more
13 Apr 2023 13:59

IN BRIEF: Destiny Pharma annual loss widens as expenses grow

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to GBP7.7 million for 2022 from GBP6.3 million in 2021. Administrative expenses increase to GBP7.4 million from GBP6.0 million a year earlier. Research & development expenditure amounts to GBP4.9 million, up from GBP3.7 million in 2021. Looking ahead, Destiny Pharma says it will focus on completing the manufacturing scale-up to deliver clinical trial material for the NTCD-M3 clinical programme being run by our partner Sebela. Chief Executive Officer Neil Clark says: "Destiny Pharma has made good progress in 2022 and in the first quarter of 2023."

Read more
6 Apr 2023 15:42

UK earnings, trading statements calendar - next 7 days

Friday 7 April 
no events scheduled 
Monday 10 April 
no events scheduled 
Tuesday 11 April 
Devolver Digital IncFull Year Results
JTC PLCFull Year Results
Wednesday 12 April 
Argentex Group PLCQ3 Results
DP Eurasia NVFull Year Results
Everyman Media Group PLCFull Year Results
LBG Media PLCFull Year Results
Tharisa PLCTrading Statement
Thursday 13 April 
Brooks Macdonald Group PLCTrading Statement
Churchill China PLCFull Year Results
Destiny Pharma PLCFull Year Results
discoverIE Group PLCTrading Statement
Foresight Group Holdings LtdTrading Statement
Imperial Brands PLCTrading Statement
LSL Property Services PLCFull Year Results
Norcros PLCTrading Statement
PZ Cussons PLCTrading Statement
Tesco PLCFull Year Results
XP Power LtdTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
4 Apr 2023 11:33

Destiny Pharma upbeat on infection prevention study

(Sharecast News) - Destiny Pharma said in an update on Tuesday that its novel medicine for preventing life-threatening infections, 'NTCD-M3', had been shown to colonise the gut successfully in a C difficile infection (CDI) model study after the administration of fidaxomicin.

Read more
24 Mar 2023 15:34

Destiny publishes 'important' research on its preoperative treatment candidate

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the publication of landmark clinical data for 'XF-73' on Friday, in the US-based peer-reviewed journal Infection Control & Hospital Epidemiology.

Read more
16 Mar 2023 06:54

IN BRIEF: Destiny Pharma raises GBP7.3 million total in equity raise

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Gets 33% take-up of open offer of shares, raising GBP340,000. Destiny raises GBP7.3 million gross in total from the open offer, plus a share placing and subscription, all at 35 pence per share. Net proceeds are GBP6.7 million, which will be used to support a collaboration agreement in the US with Sebela Pharmaceuticals for NTCD-M3, Destiny's lead asset for the prevention of clostridioides difficile infection recurrence.

Read more
24 Feb 2023 14:28

Destiny shares fall on fundraise discount despite USD570 million deal

(Alliance News) - Destiny Pharma PLC on Friday said that it has signed a collaboration agreement with Sebela Pharmaceuticals for NTCD-M3, its lead asset for the prevention of clostridioides difficile infection recurrence.

Read more
25 Jan 2023 20:03

TRADING UPDATES: Appreciate gets court date; Corcel completes sale

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
22 Dec 2022 14:06

Destiny Pharma jumps on 2022 progress

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its progress in 2022 on Thursday, including working to finalise a partnering agreement for 'NTCD-M3', which it described as its "most advanced" clinical programme, targeted at infection prevention.

Read more
22 Dec 2022 12:10

LONDON MARKET MIDDAY: UK stocks rise as Paris and Frankfurt head lower

(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buoyant.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.